

1 Diagnostics for detection and surveillance of priority
2 epidemic-prone diseases in Africa: an assessment of
3 testing capacity and laboratory strengthening needs.

4
5 Aytnew Ashenafi^{1*}, Olajumoke Sule², Trevor Peter³, Silver Mashate⁴, Osborn
6 Otieno⁵, Abebaw Kebede¹, John Oio¹, Kekeletso Kao⁶, Jane Carter⁷, Toni Whistler⁵,
7 Nqobile Ndlovu⁴, Yenew Kebede¹

8 ¹Centre of Laboratory Systems Division, Africa Centres for Disease Control and
9 Prevention, Addis Ababa, Ethiopia.

10 ²International Health Regulations Strengthening Project, Health Protection
11 Operations, United Kingdom Health Security Agency, London, United Kingdom.

12 ³Clinton Health Access Initiative, Boston, Massachusetts, United States of America.

13 ⁴African Society for Laboratory Medicine, Addis Ababa, Ethiopia.

14 ⁵Technical Advice and Partnerships Department, The Global Fund to Fight AIDS,
15 Tuberculosis and Malaria, Geneva, Switzerland.

16 ⁶Diagnostic System Strengthening Unit, FIND , Geneva, Switzerland.

17 ⁷Clinical and Diagnostics Programme, Amref Health Africa, Nairobi, Kenya.

18
19 *Corresponding author

20 E-mail: AytnewA@africacdc.org (AA)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

21 Abstract

22 In 2023, Africa experienced 180 public health emergencies, of which 90% were
23 infectious diseases and 75% were related to zoonotic diseases. Testing capacity for
24 epidemic-prone diseases is essential to enable rapid and accurate identification of
25 causative agents, and for action to prevent disease spread. Moreover, testing is
26 pivotal in monitoring disease transmission, evaluating public health interventions, and
27 informing targeted resource allocation during outbreaks. An online, self-assessment
28 survey was conducted in African Union Member States to identify major challenges in
29 testing for epidemic-prone diseases. The survey assessed current capacity for
30 diagnosing priority epidemic-prone diseases at different laboratory levels. It explored
31 challenges in establishing and maintaining testing capacity to improve outbreak
32 response and mitigate public health impact. Survey data analysed diagnostic
33 capacity for priority infectious diseases, diagnostic technologies in use, existing
34 surveillance programmes and challenges limiting diagnostic capacity, by country. The
35 survey result from 15 Member States who responded to the survey, showed high
36 variability in testing capacity and technologies across countries and diverse factors
37 limiting testing capacity for certain priority diseases like dengue and Crimean-Congo
38 haemorrhagic fever. At the same time, there is better diagnostic capacity for
39 coronavirus disease 2019 (COVID-19), polio, and measles due to previous
40 investments. Unfortunately, many countries are not utilising multiplex testing, despite
41 its potential to improve diagnostic access. The challenges of limited laboratory
42 capacity for testing future outbreaks are indeed significant. Recent disease outbreaks
43 in Africa have underscored the urgent need to strengthen diagnostic capacity and
44 introduce cost-effective technologies. Small sample sizes and differing disease
45 prioritisation within each country limited the analysis. These findings suggest the

46 benefits of evaluating laboratory testing capacity for epidemic-prone diseases and
47 highlight the importance of effectively addressing challenges to detect diseases and
48 prevent future pandemics.

49

50 Introduction

51 In 2023, Africa has documented more than 168 public health events affecting 45
52 African Union Member States mostly infectious disease outbreaks including mpox,
53 diphtheria, dengue, Lassa fever, measles, polio, Rift Valley fever and cholera. These
54 outbreaks continue to expand rapidly and affect many countries on the continent.
55 Since the beginning of 2024, a total of 26,122 cholera cases (3,396 confirmed;
56 22,726 suspected) with 663 deaths were reported from 12 African countries; 4,451
57 cases of measles (178 confirmed; 4,273 suspected) and 51 deaths were reported
58 from seven African countries; and for diphtheria 1,573 cases were reported (904
59 confirmed; 669 suspected) with four deaths from two African countries (1-4).

60 The International Health Regulations (IHR, 2005) identify disease mapping, health
61 risk assessment and resource prioritisation as among the core capabilities of public
62 health emergency preparedness and response systems (5). Recurrent outbreaks of
63 emerging and re-emerging pathogens have revealed major gaps in these systems in
64 countries on the African continent. Key mechanisms to prevent recurrent disease
65 outbreaks include early detection of infectious diseases in the community, rapid
66 pathogen identification, and integrated disease surveillance. Surveillance and
67 response capacity is limited in many African countries, especially in the context of
68 COVID-19, Ebola virus disease (EVD), and in detection and monitoring of
69 antimicrobial resistance (6). As the recent EVD, COVID-19 and mpox outbreaks

70 highlight, a major paradigm shift is required to establish effective infrastructure and
71 mechanisms for outbreak detection, and common frameworks for preparedness and
72 national public health responses to manage future epidemics (7).

73 The Africa Centres for Disease Control and Prevention (Africa CDC) has drawn up a
74 preliminary list of priority epidemic-prone diseases for Africa using a risk ranking and
75 analysis tool to identify the target infectious diseases for epidemic preparedness and
76 response actions (8), and to inform research and technology development and
77 disease control innovations such as development and provision of vaccines,
78 diagnostics, and therapeutics. For example, EVD, cholera and COVID-19 scored the
79 highest for disease severity, risk and epidemic potential, as well as the need for
80 preparedness through vaccine availability, and medical and non-medical
81 countermeasures. The disease ranking processes changes every time as more
82 evidence comes in.

83 The ability to respond effectively to disease outbreaks depends on several factors,
84 including laboratory capacity, a trained health workforce, and robust surveillance
85 systems (9), which are public health systems that rapidly diagnose and contain the
86 spread of infectious diseases. While significant diagnostic capacity has been
87 established over the past two decades for major endemic diseases such as
88 HIV/AIDS, tuberculosis (TB), malaria and more recently COVID-19, testing capacity
89 for other epidemic-prone infections is more limited. Therefore, a comprehensive
90 approach is needed to address the gaps in pandemic preparedness and health
91 systems' resilience (10, 11).

92 The Africa CDC undertook a survey of African Union Member States on disease
93 priorities, laboratory capacities and public surveillance systems to help identify major
94 challenges faced in building testing capacity for outbreak detection and response for

95 epidemic-prone diseases in African countries. The findings of this survey are
96 presented in this paper.

97

98 **Methods**

99 **Survey description**

100 All 55 African Union Member States were invited to participate in a self-assessment
101 survey of laboratory testing capacity and surveillance of 22 epidemic-prone diseases
102 between February and April 2023. These diseases were selected through a risk
103 ranking and prioritisation exercise undertaken by Africa CDC in collaboration with the
104 European Centre for Disease Prevention and Control in 2022 (8).

105 **Survey instrument**

106 The survey instrument was developed and validated in consultation with members of
107 the Africa Laboratory Technical Working Group (S1 questionnaire file). It included
108 questions on disease testing capacity, technology in use, healthcare system level
109 and presence of surveillance programmes. Additionally, questions addressed
110 multiplex testing capacity and challenges faced.

111 Participants were asked to rank their capacity to diagnose the priority epidemic-prone
112 diseases (S2 list file) on a five-point Likert scale (from 1–5), with 5 being the highest.

113 Quantitative questions included information on disease testing capacity across
114 countries' healthcare systems, standard methods used to diagnose diseases (PCR,
115 multiplex PCR, lateral flow assays, ELISA, etc.), biosecurity, sample transport, data
116 systems, staffing and existing surveillance programmes. Qualitative questions were

117 also included to allow respondents to add relevant comments, and to identify
118 countries' most significant challenges and the support needed to ensure adequate
119 diagnostic capacity for future outbreaks and epidemics. The survey tool was
120 developed in a Microsoft Excel format using dropdown lists to make it user-friendly.
121 The tool was provided in English and French, pre-tested, amended and distributed
122 online to respondents (S1 questionnaire file).

123 The first section of the survey comprised 8- questionnaire for disease testing capacity
124 to correlate the epidemic-prone disease to the capacity of diagnosis and technology
125 in use and surveillance programmes for these diseases. The respondent only
126 completes the boxes. Some of these boxes have a dropdown menu so that they can
127 only select answers. The tool allows countries to add a comment describing their
128 testing method and asking about the standard methods used to diagnose diseases
129 (PCR, Multiplex PCR, Lateral Flow Assay, ELISA, and others). Based on the
130 responses, the ability to diagnose the twenty-two priority epidemic-prone diseases
131 were rated on a five-point scale from 1 to 5, with 5 representing the highest score..

132 The second survey has 3-questionnaire for multiplex testing capacity and panel of
133 multiplex testing, and levels of laboratory testing capacity across Member States'
134 healthcare systems.

135 The third survey has 8-miscellaneous and 3-qualitative questionnaires on sample
136 transport, biosecurity, data systems and staffing. Some qualitative questions were
137 included to get a general sense of the support countries need/want and explore
138 countries' biggest challenges to ensuring diagnostic capacity to be ready for a future
139 epidemic.

140

141 **Dissemination of the survey tool to countries and data** 142 **collection**

143 All African countries were invited to participate in the survey, targeting national public
144 health laboratory directors, managers and heads of reference laboratories. We
145 collected the informed consent form from online survey links obtained from a network
146 of laboratories that got a request to participate in a survey. Data were collected from
147 February to April 2023.

148

149 **Data entry and analysis**

150 Data were entered into SPSS 2023 and Excel for data analysis and visualisation.

151 **Ethics Considerations**

152 Ethics approval was not sought for the following reasons.

153 The survey pertained to member state diagnostic capacity did not include data on
154 individual patients or vulnerable people. The survey instrument was developed in
155 consultation with members of Africa CDC Laboratory Technical Working
156 Group. Participation by member states was voluntary following informed
157 consent. Responses were stored securely on Africa CDC platform and published
158 results of the survey Responses were via online methodology and results of the
159 survey are anonymised and cannot be traced to member states.

160

161 **Results**

162 **Survey respondents**

163 Participants from 15 of 55 (27%) Member States responded to the survey (Fig 1).
164 Respondents were distributed as follows: five (50%) from the southern region, four
165 (27%) from the western region, three (21%) from the eastern region, two (29%) from
166 the northern region, and one (11%) from the central region. The survey was
167 completed by laboratory directors (7) and senior technical staff members (8) working
168 at either national public health institutes (12) or ministries of health (3).



169


170 **Fig 1. Map showing countries that participated in the survey (n=15)**

171

172 **Disease testing capacity by laboratory level**

173 Capacity for diagnosing infectious diseases varied based on the disease, country and
174 laboratory level (Fig 2). Testing for viral haemorrhagic fevers was conducted at
175 central public health laboratories and tertiary care hospital laboratories, while testing

176 for COVID-19, meningococcal meningitis, cholera, measles and dengue was
177 conducted at laboratories ranging from reference to district level.



178
179 **Fig 2. Stacked bar graph showing the percentage of countries (n=15) that can**
180 **test for the specified priority epidemic-prone disease at each tier of the**
181 **laboratory system.**


182
183 The most common testing technology reported for diagnosing causative agents of
184 epidemic-prone diseases was real-time polymerase chain reaction (qPCR) followed
185 by enzyme-linked immunosorbent assay (ELISA). There were differences in testing
186 capacity and technology across the participating countries. All 15 countries reported
187 use of PCR testing for COVID-19. Measles and mpox were the next most common
188 diseases diagnosed by PCR. Among Member States using PCR for testing, open-
189 source instruments were available in 60% of national public health laboratories, 47%

190 of regional and tertiary laboratories, and 20% of secondary care laboratories. ELISA
191 was routinely performed to diagnose seven diseases (measles, yellow fever, CCHF,
192 Rift Valley fever, dengue, Zika and chikungunya) across eleven countries, with
193 measles being the most common. Among bacterial infections, few countries reported
194 using molecular techniques for diagnosis, with between one and three countries each
195 reporting molecular techniques for diagnosing cholera, plague, anthrax, and
196 meningococcal disease. Two countries reported conducting culture for diagnosing
197 cholera, plague, and meningococcal disease. Some countries did not report
198 diagnostic capacity for testing certain infections. Eleven of the 15 countries did not
199 test for anthrax, and ten countries did not perform testing for plague and rabies due
200 to lack of capacity.

201

202 **Surveillance programmes for priority infectious diseases**

203 The three most common surveillance programmes that countries were actively
204 running during the survey were COVID-19, measles, and polio (Fig 3). Twelve
205 countries reported having surveillance programmes for between three and twelve
206 priority diseases. Several countries reported both the availability of PCR testing and
207 the presence of surveillance programmes for some priority diseases, for example,
208 plague, anthrax, cholera and meningitis. For polio, ten countries reported having
209 surveillance programs, but only six countries indicated they have PCR diagnostic
210 capacity.



211


212 **Fig 3. Number of countries reporting capacity for laboratory diagnosis (PCR**
213 **and/or ELISA) of the priority epidemic-prone diseases and current active**
214 **surveillance systems.**

215

216 **Epidemic-prone disease priorities for diagnosis and** 217 **surveillance**

218 There were large differences in countries' priorities for disease diagnosis and
219 surveillance. Thirteen countries reported COVID-19 as the highest priority for their
220 country, whereas two countries reported dengue fever as their highest priority. Others
221 reported avian influenza, plague, anthrax, respiratory syncytial virus (RSV) disease,

222 chikungunya, and EVD as their priority. There were disparities between priority and
223 the capacity to diagnose diseases. For example, while COVID-19 was reported to be
224 a high-priority disease with high diagnostic capacity among countries, four countries
225 reported polio as a high-priority disease but with low diagnostic capacity using the
226 Likert scale 1-5 for both capacity to diagnosis and priority (Fig 4).



227
228 **Fig 4. Self-reported testing capacity against the country priority for each**
229 **epidemic-prone disease across the 15 Member States participating in the**
230 **survey.** Blue marker represents viral diseases, and the orange marker designates
231 bacterial diseases. Inputs were provided on a Likert scale (1-5, with 5 being the
232 highest priority), the average scores across reporting countries for the pathogen are
233 plotted.

234 **Need for laboratory multiplexing testing capacity.**

235 Most respondents indicated the need for multiplex diagnostic testing capacity for
236 infectious respiratory illnesses and arbovirus infections followed by meningitis (Table
237 1). For some diseases, the perceived need was less commonly reported.

238 **Table 1. Number of countries reporting the need for multiplex testing by**
239 **disease and/or pathogens.**


| Diseases (pathogens) for which multiplex testing was reported as most needed | Number of countries n=14 (%) |
|---|---------------------------------|
| Infectious respiratory illness (influenza virus, RSV, SARS-CoV-2) | 11 (79%) |
| Arbovirus (dengue, chikungunya, Zika, yellow fever, Rift Valley fever, West Nile viruses, encephalitis) | 9 (64%) |
| Meningitis (including <i>Neisseria meningitidis</i> , <i>Streptococcus pneumoniae</i>) | 7 (50%) |
| Diarrhoeal illness including cholera | 3 (21%) |
| Viral haemorrhagic fevers (including CCHF virus, Marburg virus, Lassa virus) | 3 (21%) |

240

241 **Reported challenges limiting diagnostic capacity for future** 242 **epidemics**

243 Eighty-five per cent of countries that responded to the survey cited inconsistent
244 laboratory supplies such as PCR reagents, extraction kits and consumables as the
245 primary challenge to developing laboratory capacity to diagnose future epidemics.

246 This was followed by inadequate infrastructure (45%), limited government funding
247 (43%), inadequate equipment management (35%) and inadequate human resources
248 (25%) (Fig 5).



249
250 **Fig 5. Reported gaps in laboratory diagnostics capacity limiting support for**
251 **future epidemics.**

252

253 Discussion

254 The survey aimed to understand countries' laboratory diagnostic needs for epidemic
255 preparedness and response. The results offered insights into existing laboratory
256 capacity for priority epidemic-prone diseases across 15 countries. They provided an
257 overview of the capacity within functional tiered laboratory networks across various
258 African Union Member States. These capacities are crucial for implementing the IHR
259 and addressing urgent public health threats such as COVID-19, EVD, measles,
260 CCHF, and others.

261 In recent years, the Africa region has experienced a surge in outbreaks and
262 epidemics, threatening the health of populations and socio-economic stability, with
263 potential global ramifications (12). Reported disease outbreaks include yellow fever,

264 Rift Valley fever, mpox, measles, CCHF, dengue fever, chikungunya, EVD, Marburg
265 virus disease, cholera, diphtheria, and COVID-19. However, Africa's inadequate
266 disease diagnosis and surveillance systems hinder the prediction, prevention and
267 effective management of emerging infectious diseases (13). Delayed detection of
268 outbreaks is attributed to a lack of real-time surveillance, suboptimal laboratory
269 networks, limited diagnostic capabilities, inadequate resources, and insufficient
270 technical and managerial capacities.

271 This survey showed that the capacity for diagnosing infectious diseases varied by
272 disease, country, and laboratory level within tiered networks. The most common
273 technology for diagnosing epidemic-prone diseases was PCR, followed by ELISA. All
274 15 participating countries reported the use of PCR testing for COVID-19, highlighting
275 the improvements in diagnostics from the COVID-19 pandemic. In contrast, priority
276 diseases such as polio and plague had limited PCR testing capacity. These results
277 may reflect differing country priorities, levels of laboratory testing maturity, and/or the
278 availability of national and external funds to diagnose priority pathogens. The findings
279 suggest that policy and decision-makers have shown a consistent commitment to
280 improving laboratory capacity and system development, as demonstrated by the high
281 capacity to diagnose COVID-19; however, our assessment has also uncovered
282 significant deficiencies in disease diagnostic capacity, particularly at different levels of
283 the tiered laboratory networks that handle epidemic-prone diseases.

284 Lower-level laboratories exhibited weaknesses in testing for diseases such as Rift
285 Valley fever, CCHF, plague, dengue fever and Zika, which were predominantly
286 conducted at central and regional laboratories, compared to their capabilities for
287 diagnosing COVID-19, polio, measles, mpox, cholera and meningitis. This disparity
288 reflects historical prioritisation and investment in testing for specific diseases,

289 technological advancements, biosafety concerns, and the diversity and availability of
290 funding resources. The COVID-19 crisis underscores the world's historical
291 unpreparedness to detect and respond to emerging infectious diseases (14). Recent
292 outbreaks of diseases such as Lassa fever, EVD, Marburg virus disease, diphtheria,
293 anthrax, and cholera across the continent highlight the urgent need to strengthen
294 diagnostic capacity for emergency response and outbreak management. Lassa
295 fever's expanding geographical spread in West Africa underscores the evolving
296 epidemiology of infectious diseases and the necessity for all countries to possess
297 resilient and adaptable diagnostic capabilities (15).

298 Inadequate diagnostic testing remains a significant issue in African countries (16, 17),
299 particularly at lower-level laboratories. Many commercially available diagnostic tools
300 do not meet the needs of these laboratories or cannot be used due to weak
301 infrastructure. Increased investment in testing capacity at lower-level laboratories is
302 crucial, along with developing and implementing appropriate technologies for
303 diagnosing epidemic-prone diseases. Some tests are available in multiplex format,
304 enabling the detection of multiple pathogens in a single sample for both surveillance
305 and clinical management purposes. Establishing diagnostic capacity for priority
306 diseases of epidemic potential through integrated testing within existing laboratory
307 capacity and with multiplex testing will improve epidemic preparedness, aid early
308 detection and response, and help prevent outbreaks from becoming pandemics (18,
309 19).

310 Limited access to diagnostic testing has been a bottleneck in the early detection of
311 priority diseases in Africa (20-22). Diagnostic capacity has often focused on diseases
312 such as HIV, TB, malaria, and more recently, COVID-19 (23, 24). However,
313 laboratories and health systems established for these infections can also be used to

314 detect other priority diseases of epidemic potential, thereby expanding the range of
315 pathogen detection capacity in African Union Member States using existing
316 methodologies.

317 This survey highlights that the effectiveness of response measures is impeded by
318 various factors, including limited laboratory capacities, difficulties in accessing
319 diagnostic services, shortages of human resources, and fragmented surveillance
320 systems. These challenges exacerbate the complexities of response efforts in
321 numerous countries within the Africa region. The integration of testing and effective
322 use of existing diagnostic platforms and laboratory infrastructure were demonstrated
323 with SARS-CoV-2 testing during the COVID-19 pandemic.

324 The limitations of this survey included reliance on self-reporting and the limited
325 number of countries that responded. Despite these limitations, the survey results
326 provided valuable insights into diagnostic capacity, disease priorities, surveillance
327 systems and current challenges to the diagnosis of epidemic-prone diseases and has
328 highlighted gaps that urgently need to be addressed to enhance epidemic
329 preparedness, facilitate early disease detection and response, and mitigate the risk of
330 outbreaks escalating into pandemics.

331 Conclusion

332 The increased technical capacity for diagnosing infectious diseases since the
333 COVID-19 epidemic is evident. With ongoing outbreaks of diseases such as yellow
334 fever, Rift Valley fever, mpox, measles, CCHF, dengue fever, chikungunya, EVD,
335 Marburg virus disease, cholera and diphtheria across the continent, there is an
336 urgent need to address the gaps in diagnostic capacity and disease surveillance.
337 Recognising the varying country priorities, expanding point-of-care and multiplex

338 testing for syndromic disease surveillance, and monitoring changes in epidemiology
339 are crucial steps to enhance readiness for detecting epidemic-prone diseases.
340 Countries need to prioritise rapid diagnostic tests and portable technologies while
341 strengthening national and regional laboratory networks. This requires updating
342 infrastructure, improving the laboratory supply chain, and investing in staff training
343 and development.

344 Acknowledgements

345 We express our gratitude to the Ministry of Health of participated countries and to the
346 numerous colleagues at our respective institutions who have engaged in discussions,
347 provided valuable input, and offered feedback on the paper. Their contributions have
348 significantly enhanced the quality of the final manuscript. The authors would like to
349 express their gratitude to Africa Laboratory Technical Working Group (AfLTWG)
350 members. The contents of this paper are solely the responsibility of the authors.

351 Supporting information

352 S1 laboratory capacity questionnaire (XLS)

353 S2 list of epidemic-prone diseases (DOCX)

354 References

355 1. World Economic Forum. Building resilient healthcare systems in Africa with a
356 focus on outbreaks and epidemics. 2023. Available from:

357 <https://www.weforum.org/agenda/2023/07/building-resilient-healthcare->

358 [systems-in-africa-with-a-focus-on-outbreaks-and-epidemics/](https://www.weforum.org/agenda/2023/07/building-resilient-healthcare-systems-in-africa-with-a-focus-on-outbreaks-and-epidemics/)

- 359 2. Moyo E, Mhango M, Moyo P, Dzinamarira T, Chitungo I, Murewanhema G.
360 Emerging infectious disease outbreaks in Sub-Saharan Africa: Learning from
361 the past and present to be better prepared for future outbreaks. *Front Public*
362 *Health*. 2023;11:1049986.
- 363 3. Africa Centres for Disease Control and Prevention. Building Testing Capacity
364 for Epidemic-Prone Diseases. 2023. Available from:
365 [https://africacdc.org/download/building-testing-capacity-for-epidemic-prone-](https://africacdc.org/download/building-testing-capacity-for-epidemic-prone-diseases)
366 [diseases](https://africacdc.org/download/building-testing-capacity-for-epidemic-prone-diseases)
- 367 4. Africa Centres for Disease Control and Prevention. Disease Outbreaks:
368 Information on disease outbreaks from Africa CDC [Internet]. [cited November
369 2023]. Available from: <https://africacdc.org/disease-outbreak/>.
- 370 5. Hayman DTS, Barraclough RK, Muglia LJ, McGovern V, Afolabi MO, N'Jai AU,
371 et al. Addressing the challenges of implementing evidence-based prioritisation
372 in global health. *BMJ Glob Health*. 2023;8(6).
- 373 6. Adebisi YA, Rabe A, Lucero-Prisno III DE. COVID-19 surveillance systems in
374 African countries. *Health Promot Perspect*. 2021;11(4):382-92.
- 375 7. Aborode AT, Hasan MM, Jain S, Okereke M, Adedeji OJ, Karra-Aly A, et al.
376 Impact of poor disease surveillance system on COVID-19 response in Africa:
377 Time to rethink and rebuilt. *Clin Epidemiol Glob Health*. 2021;12:100841.
- 378 8. Africa Centres for Disease Control and Prevention. Risk Ranking and
379 Prioritization of Epidemic-Prone Diseases. 2023. Available from:
380 [https://africacdc.org/download/risk-ranking-and-prioritization-of-epidemic-](https://africacdc.org/download/risk-ranking-and-prioritization-of-epidemic-prone-diseases/)
381 [prone-diseases/](https://africacdc.org/download/risk-ranking-and-prioritization-of-epidemic-prone-diseases/)


- 382 9. Nachega JB, Nsanzimana S, Rawat A, Wilson LA, Rosenthal PJ, Siedner MJ,
383 et al. Advancing detection and response capacities for emerging and re-
384 emerging pathogens in Africa. *Lancet Infect Dis.* 2023;23(5):e185-e9.
- 385 10. Ewert B, Wallenburg I, Winblad U, Bal R. Any lessons to learn? Pathways and
386 impasses towards health system resilience in post-pandemic times. *Health*
387 *Econ Policy Law.* 2023;18(1):66-81.
- 388 11. Rajapaksha R, Khatri RB, Abeysena C, Wijesinghe MSD, Endalamaw A,
389 Thomas TK, et al. Success and challenges of health systems resilience-
390 enhancing strategies for managing Public Health Emergencies of International
391 Concerns (PHEIC): A systematic review protocol. *BMJ Open.*
392 2022;12(11):e067829.
- 393 12. In: Jamison DT, Gelband H, Horton S, Jha P, Laxminarayan R, Mock CN, et
394 al., editors. *Disease Control Priorities: Improving Health and Reducing*
395 *Poverty.* Washington (DC): The World Bank. 2017. Available from:
396 <https://www.ncbi.nlm.nih.gov/books/NBK525302/>
- 397 13. Nyaruaba R, Okoye CO, Akan OD, Mwaliko C, Ebido CC, Ayoola A, et al.
398 Socio-economic impacts of emerging infectious diseases in Africa. *Infect Dis*
399 *(Lond).* 2022;54(5):315-24.
- 400 14. Craven M, Sabow A, Van der Veken L, Wilson M. Not the last pandemic:
401 Investing now to reimagine public-health systems2021. Available from:
402 [https://www.mckinsey.com/industries/public-sector/our-insights/not-the-last-](https://www.mckinsey.com/industries/public-sector/our-insights/not-the-last-pandemic-investing-now-to-reimagine-public-health-systems)
403 [pandemic-investing-now-to-reimagine-public-health-systems.](https://www.mckinsey.com/industries/public-sector/our-insights/not-the-last-pandemic-investing-now-to-reimagine-public-health-systems)
- 404 15. Balogun OO, Akande OW, Hamer DH. Lassa Fever: An Evolving Emergency
405 in West Africa. *Am J Trop Med Hyg.* 2020;104(2):466-73.

- 406 16. Brehm B. The case for investment: Insights from five African manufacturers on
407 local manufacturing of diagnostic tools2023. Available from:
408 [https://www.path.org/our-impact/articles/investment-insights-local-](https://www.path.org/our-impact/articles/investment-insights-local-manufacturing-diagnostic/)
409 [manufacturing-diagnostic/](https://www.path.org/our-impact/articles/investment-insights-local-manufacturing-diagnostic/).
- 410 17. The Global Fund. Results Report 2023. Geneva, Switzerland: The Global
411 Fund; 2023 Available from:
412 <https://www.theglobalfund.org/en/results/#download>.
- 413 18. Ramos PIP, Marcilio I, Bento AI, Penna GO, de Oliveira JF, Khouri R, et al.
414 Combining Digital and Molecular Approaches Using Health and Alternate Data
415 Sources in a Next-Generation Surveillance System for Anticipating Outbreaks
416 of Pandemic Potential. JMIR Public Health Surveill. 2024;10:e47673.
- 417 19. Calderaro A, Piccolo G, Chezzi C. The Laboratory Diagnosis of Malaria: A
418 Focus on the Diagnostic Assays in Non-Endemic Areas. Int J Mol Sci.
419 2024;25(2).
- 420 20. African Society for Microbiology. Bringing diagnostic testing closer to
421 communities. Lab Culture. 2022. Available from: [https://aslm.org/wp-](https://aslm.org/wp-content/uploads/2022/06/ASLM_Lab_Culture_Issue_27.pdf)
422 [content/uploads/2022/06/ASLM_Lab_Culture_Issue_27.pdf](https://aslm.org/wp-content/uploads/2022/06/ASLM_Lab_Culture_Issue_27.pdf)
- 423 21. Kobia F, Gitaka J. COVID-19: Are Africa's diagnostic challenges blunting
424 response effectiveness? AAS Open Res. 2020;3:4.
- 425 22. Heidt B, Siqueira WF, Eersels K, Diliën H, van Grinsven B, Fujiwara RT, et al.
426 Point of Care Diagnostics in Resource-Limited Settings: A Review of the
427 Present and Future of PoC in Its Most Needed Environment. Biosensors
428 (Basel). 2020;10(10).


- 429 23. Mfuh KO, Abanda NN, Titanji BK. Strengthening diagnostic capacity in Africa
430 as a key pillar of public health and pandemic preparedness. PLOS Glob Public
431 Health. 2023;3(6):e0001998.
- 432 24. Chanda-Kapata P, Ntoumi F, Kapata N, Lungu P, Mucheleng'anga LA,
433 Chakaya J, et al. Tuberculosis, HIV/AIDS and Malaria Health Services in sub-
434 Saharan Africa - A Situation Analysis of the Disruptions and Impact of the
435 COVID-19 Pandemic. Int J Infect Dis. 2022;124 Suppl 1:S41-s6.

| Pathogen type | Name | Central / Regional Reference | Tertiary Hospital | Secondary Hospital | Primary Care Hospital |
|---------------|---------------------------------|------------------------------|-------------------|--------------------|-----------------------|
| 5 Bacterium | Plague | 26 | 0 | 0 | 0 |
| 10 Bacterium | Meningococcal disease | 20 | 13 | 26 | 13 |
| 12 Bacterium | Cholera | 33 | 13 | 13 | 6 |
| 4 Bacterium | Anthrax | 26 | 6 | 0 | 0 |
| 13 Virus | Zika | 33 | 13 | 13 | 0 |
| 60 Virus | Yellow fever | 60 | 0 | 6 | 0 |
| 16 Virus | Rift Valley fever | 40 | 6 | 6 | 0 |
| 7 Virus | Respiratory syncytial virus | 20 | 13 | 13 | 0 |
| 11 Virus | Rabies | 33 | 0 | 0 | 0 |
| 2 Virus | Poliovirus | 40 | 6 | 0 | 0 |
| 1 Virus | Mpox | 50 | 20 | 0 | 0 |
| 3 Virus | Measles | 50 | 13 | 6 | 13 |
| 17 Virus | Marburg virus | 33 | 13 | 13 | 0 |
| 18 Virus | Lassa fever | 26 | 6 | 0 | 0 |
| 8 Virus | Influenza | 40 | 6 | 20 | 0 |
| 20 Virus | Ebola (Zaire) | 50 | 6 | 0 | 0 |
| 19 Virus | Ebola (Sudan) | 50 | 6 | 0 | 0 |
| 21 Virus | Dengue fever | 33 | 13 | 6 | 13 |
| 22 Virus | Crimean-Congo hemorrhagic fever | 33 | 0 | 0 | 0 |
| 9 Virus | COVID-19 | 20 | 13 | 20 | 73 |
| 15 Virus | Chikungunya | 33 | 13 | 6 | 0 |
| 6 Virus | Avian Influenza | 33 | 6 | 6 | 0 |

Percentage of facilities at each tier of the laboratory network that had the ability to test for the specific




| Pathogen type | Disease | PCR | ELISA | Surveillance |
|---------------|---------------------------------|-----|-------|--------------|
| 5 Bacterium | Plague | 5 | 0 | 5 |
| 10 Bacterium | Meningococcal disease | 9 | 0 | 9 |
| 12 Bacterium | Cholera | 8 | 0 | 8 |
| 4 Bacterium | Anthrax | 5 | 0 | 5 |
| 13 Virus | Zika | 6 | 3 | 5 |
| 14 Virus | Yellow fever | 9 | 4 | 6 |
| 16 Virus | Rift Valley fever | 6 | 1 | 3 |
| 7 Virus | Respiratory syncytial virus | 6 | 0 | 5 |
| 11 Virus | Rabies | 5 | 0 | 6 |
| 2 Virus | Poliovirus | 6 | 0 | 10 |
| 1 Virus | Mpox | 12 | 0 | 7 |
| 3 Virus | Measles | 11 | 10 | 11 |
| 17 Virus | Marburg virus | 7 | 0 | 4 |
| 18 Virus | Lassa fever | 7 | 0 | 3 |
| 8 Virus | Influenza | 9 | 0 | 8 |
| 20 Virus | Ebola (Zaire) | 7 | 0 | 5 |
| 19 Virus | Ebola (Sudan) | 7 | 0 | 5 |
| 21 Virus | Dengue fever | 9 | 3 | 8 |
| 22 Virus | Crimean-Congo hemorrhagic fever | 6 | 1 | 3 |
| 9 Virus | COVID-19 | 15 | 0 | 12 |
| 15 Virus | Chikungunya | 7 | 2 | 4 |
| 6 Virus | Avian Influenza | 6 | 0 | 5 |



| Pathogen type | Pathogen (Disease) | Pathogen (Disease) | No Countries | Total Likert Dx capability | Diagnostic capability | Number Countries | Priority | Disease Priority |
|---------------|--|---------------------------------|--------------|----------------------------|-----------------------|------------------|----------|------------------|
| 1 Virus | Avian Influenza | Avian Influenza | 7 | 26 | 3.7 | 10 | 32 | 3.2 |
| 19 Bacterium | Bacillus anthracis (anthrax) | Bacillus anthracis | 7 | 22 | 3.1 | 10 | 38 | 3.8 |
| 2 Virus | Chikungunya virus | Chikungunya virus | 9 | 38 | 4.2 | 10 | 38 | 3.8 |
| 4 Virus | COHF virus | Cribean-Congo hemorrhagic fever | 7 | 19 | 2.7 | 6 | 18 | 3.0 |
| 5 Virus | Dengue virus (dengue fever) | Dengue virus | 10 | 29 | 2.9 | 9 | 24 | 2.7 |
| 6 Virus | Ebola virus [species Sudan] (Ebola v | Ebola virus [species Sudan] | 9 | 27 | 3.0 | 9 | 31 | 3.4 |
| 7 Virus | Ebola virus [species Zaire] (Ebola vir | Ebola virus [species Zaire] | 9 | 29 | 3.2 | 9 | 36 | 4.0 |
| 8 Virus | Influenza virus | Influenza virus | 10 | 35 | 3.5 | 12 | 48 | 4.0 |
| 9 Virus | Lassa fever virus | Lassa fever virus | 9 | 28 | 3.1 | 8 | 24 | 3.0 |
| 10 Virus | Marburg virus | Marburg virus | 8 | 25 | 3.1 | 7 | 22 | 3.1 |
| 11 Virus | Measles virus | Measles virus | 12 | 48 | 4.0 | 12 | 53 | 4.4 |
| 12 Virus | Monkeypox virus (mpox) | Monkeypox virus | 13 | 47 | 3.6 | 13 | 54 | 4.2 |
| 21 Bacterium | Neisseria meningitidis (meningococ | Neisseria meningitidis | 11 | 35 | 3.2 | 12 | 54 | 4.5 |
| 13 Virus | Poliovirus | Poliovirus | 8 | 22 | 2.8 | 10 | 47 | 4.7 |
| 14 Virus | Rabies virus | Rabies virus | 7 | 22 | 3.1 | 9 | 38 | 4.2 |
| 15 Virus | Respiratory syncytial virus | Respiratory syncytial virus | 8 | 25 | 3.1 | 9 | 28 | 3.1 |
| 16 Virus | Rift Valley fever virus | Rift Valley fever virus | 8 | 25 | 3.1 | 8 | 24 | 3.0 |
| 3 Virus | SARS-CoV2 (COVID-19) | SARS-CoV2 | 14 | 64 | 4.6 | 14 | 67 | 4.8 |
| 20 Bacterium | Vibrio cholerae (cholera) | Vibrio cholerae | 11 | 41 | 3.7 | 10 | 41 | 4.1 |
| 17 Virus | Yellow fever virus | Yellow fever virus | 10 | 32 | 3.2 | 10 | 37 | 3.7 |
| 22 Bacterium | Yersinia pestis (Plague) | Yersinia pestis | 7 | 18 | 2.6 | 9 | 27 | 3.0 |
| 18 Virus | Zika virus | Zika virus | 9 | 23 | 2.6 | 9 | 24 | 2.7 |

2 2
3 3
4 4
5 5



| Disease | Priority 5 | Priority 4 | Priority 3 | Priority 2 | Priority 1 |
|---|------------|------------|------------|------------|------------|
| Dengue Fever | 1 | 1 | 3 | 2 | 2 |
| Avian Influenza | 2 | 2 | 3 | 2 | 1 |
| Crimean Congo Haemorrhagic Fever (CCHF) | 2 | 1 | 0 | 1 | 2 |
| Marburg Virus | 2 | 2 | 0 | 1 | 2 |
| Plague | 2 | 0 | 4 | 2 | 1 |
| Respiratory Syncytial Virus | 2 | 1 | 3 | 2 | 1 |
| Zika | 2 | 0 | 3 | 1 | 3 |
| Lassa Fever | 3 | 1 | 0 | 1 | 3 |
| Rift Valley Fever | 3 | 1 | 0 | 1 | 3 |
| Ebola (Sudan) | 4 | 1 | 1 | 1 | 2 |
| Rabies | 4 | 3 | 2 | 0 | 0 |
| Anthrax | 5 | 1 | 2 | 1 | 1 |
| Chikungunya | 5 | 1 | 2 | 1 | 1 |
| Influenza | 5 | 3 | 3 | 1 | 0 |
| Cholera | 6 | 1 | 2 | 0 | 1 |
| Ebola (Zaire) | 6 | 0 | 1 | 1 | 1 |
| Measles | 8 | 2 | 1 | 1 | 0 |
| Monkeypox | 8 | 1 | 2 | 2 | 0 |
| Neisseria meningitis | 8 | 2 | 2 | 0 | 0 |
| Poliovirus | 9 | 0 | 0 | 1 | 0 |
| COVID-19 | 13 | 0 | 0 | 1 | 0 |

